Millie
your market intelligence analyst
Search Results
1 results
Your search is now limited to «Tuberculosis» expert search.
Your search is now limited to only one Source. To return to results from all sources click here.
European Respiratory Journal 12/04/2019 19:05
Despite all our efforts, the disease burden of tuberculosis (TB) is not falling fast enough to reach the 2030 milestone of the End TB strategy [1]. Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis, with low treatment success rates [1]. The repurposed drug linezolid has emerged as a core drug in MDR-TB treatment regimens [2, 3], despite its toxicity, e.g. anaemia, peripheral neuropathy and gastrointestinal disorders, optic neuritis, and thrombocytopenia [4, 5]. Currently, linezolid is used off-label, as part of Group A "Medicines to be prioritised" of the World Health Organization (WHO) MDR-TB treatment guideline [2] and in several large trials [6], such as the NIX-TB and END-TB trials.

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities

Sources

Strategic Scenarios

Trends